Multifunctional Magnetic Resonance (MR) for Radiotherapy Planning in Prostate Cancer
NCT ID: NCT01006564
Last Updated: 2009-11-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
30 participants
INTERVENTIONAL
2009-03-31
2011-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
MR-simulation in Radiotherapy for Prostate Cancer
NCT03238170
Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy
NCT01834001
Functional Magnetic Resonance Imaging for High Throughput Curietherapy Planning in Prostate Cancer
NCT02516995
CT/MRI Co-registration Prostate Cancer
NCT00252460
Incorporating MR Imaging Into Prostate Radiotherapy Treatment Planning
NCT02470910
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Imaging Investigations (not radiation)
Pre-hormone therapy MRI scans will be performed as an adjunct to the patients' staging MRI scan; post hormone MRI will be done wholly for research purposes.
Other
Insertion of gold seeds into prostate for image registration.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with low-high risk histologically confirmed localised disease are eligible, with WHO performance status 0-1.
Exclusion Criteria
* No prior pelvic radiotherapy or radical prostatectomy, previous androgen therapy, patients unsuitable for radical radiotherapy, life expectancy \<10 years, previous active malignancy within last 5 years, co-morbid conditions likely to impact on the advisability of radical radiotherapy, full anticoagulation, other exclusions to MRI (e.g. hip prosthesis or fixation, claustrophobia, ferromagnetic implants).
16 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institute of Cancer Research, United Kingdom
OTHER
Royal Marsden NHS Foundation Trust
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Institute of Cancer Research
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dr Nandita deSouza
Role: PRINCIPAL_INVESTIGATOR
CRUK Clinical Magnetic Resonance Research Group
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Royal Marsden NHS Foundation Trust
Sutton, Surrey, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CCR3121
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.